Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam · Delayed Price · Currency is VND 18,400
0.00 (0.00%)
At close: Oct 30, 2026
HNX:MED Financials Overview
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 434,972 | 366,830 | 443,136 | 402,741 | 401,051 | 343,951 |
Revenue Growth | 22.39% | -17.22% | 10.03% | 0.42% | 16.60% | -34.03% |
Gross Profit Gross Profit Growth | 98,698 | 85,787 | 92,561 | 83,078 | 79,301 | 68,074 |
Operating Income Operating Income Growth | 35,719 | 22,426 | 22,193 | 14,181 | 8,634 | 8,890 |
Net Income Net Income Growth | 25,952 | 15,833 | 15,247 | 11,744 | 6,366 | 3,747 |
Earnings Per Share EPS Growth | 2090.74 | 1275.86 | 1228.59 | 946.32 | 678.00 | 597.00 |
EPS Growth | 114.33% | 3.85% | 29.83% | 39.58% | 13.57% | -84.65% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 28,297 | 31,101 | 54,611 | 63,534 | 173,583 | 94,507 |
Total Debt Total Debt Growth | 33,751 | 33,914 | 27,787 | 64,463 | 90,835 | 68,595 |
Net Cash (Debt) Net Cash Growth | -5,453 | -2,813 | 26,824 | -929.58 | 82,748 | 25,912 |
Net Cash Growth | - | - | - | - | 219.34% | -3.94% |
Net Cash Per Share Net Cash Per Share Growth | -439.34 | -226.65 | 2161.51 | -74.91 | 8813.28 | 4128.39 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 28,162 | -5,377 | 47,653 | -43,908 | 26,231 | 62,110 |
Capital Expenditures CapEx Growth | -8,382 | -9,767 | -9,979 | -40,594 | -117,270 | -54,364 |
Free Cash Flow Free Cash Flow Growth | 19,780 | -15,144 | 37,674 | -84,502 | -91,039 | 7,746 |
Free Cash Flow Growth | - | - | - | - | - | -87.20% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 22.69% | 23.39% | 20.89% | 20.63% | 19.77% | 19.79% |
Operating Margin | 8.21% | 6.11% | 5.01% | 3.52% | 2.15% | 2.58% |
Pretax Margin | 7.66% | 5.63% | 4.38% | 3.71% | 2.16% | 1.61% |
Profit Margin | 5.97% | 4.32% | 3.44% | 2.92% | 1.59% | 1.09% |
FCF Margin | 4.55% | -4.13% | 8.50% | -20.98% | -22.70% | 2.25% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 900.000 | - | - | 900.000 | 500.000 | 250.000 |
Dividend Per Share Growth | - | - | - | 80.00% | 100.00% | - |
Dividend Yield | 4.89% | - | - | 3.34% | 2.38% | 0.84% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.80 | 18.42 | 21.16 | 28.53 | 40.94 | 50.11 |
P/FCF Ratio | 11.54 | - | 8.57 | - | - | 24.24 |
PS Ratio | 0.52 | 0.80 | 0.73 | 0.83 | 0.65 | 0.55 |